Overview
Astellas Pharma Inc., headquartered in Tokyo, Japan, is a top 20 global pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. With a strong track record of proven innovation and success, the organization pursues global leadership in the primary strategic areas of immuno-oncology, genetic regulation, targeted protein degradation, blindness and regeneration, and mitochondria. Our broader business focuses include immunology, direct reprograming, circadian rhythm regulation, engineered phage therapy, synthetic biology and others with high unmet medical needs. We seek out partners who offer access to valuable resources, products, expertise, and relationships that result in products that address unmet medical needs or provide significant improvements over existing therapies. We also seek out partnerships based on game-changing technologies that enable us to evolve ways of producing therapeutics such as peptides, nucleotides, proteins, genes, cells and other new modality-related therapeutics. We have successfully partnered with key stakeholders at all levels, including entrepreneurial biotechnology and pharmaceutical companies, and government and academic laboratories. Our partnerships encompass global markets, or select geographies in major or emerging markets. We have leveraged creative and flexible partnerships, as well as strategic acquisitions to drive us toward our goal of changing tomorrow for patients and our local communities.